Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

(2016) Frank M. Balis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma

(2016) Carl Koschmann et al.   Oncotarget

Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers

(2015) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

(2015) Giulio Metro et al.   Journal of Thoracic Oncology

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

(2015) Catherine S Grasso et al.   NATURE MEDICINE

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma

(2014) Nathalène Truffaux et al.   NEURO-ONCOLOGY

Targeting MET for glioma therapy

(2014) Ahmed J. Awad et al.   Neurosurgical Focus

Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation

(2014) Kosuke Funato et al.   SCIENCE

Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

(2013) B. S. Paugh et al.   CANCER RESEARCH

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma

(2013) A. Broniscer et al.   CLINICAL CANCER RESEARCH

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma

(2013) A. Broniscer et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium

(2011) Richard Aplenc et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma

(2011) Barbara S. Paugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

(2011) Andrew S. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma

(2010) O. J. Becher et al.   CANCER RESEARCH

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

(2009) Y. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS